A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer

NCT01137994 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Neoplasms, Breast

Interventions

DRUG: Lapatinib
BIOLOGICAL: Trastuzumab
DRUG: Docetaxel
DRUG: Paclitaxel
DRUG: Vinorelbine

Sponsor

GlaxoSmithKline